Kellermair, Lukas
Fuchs, Alexandra
Eggers, Christian
Schwingenschuh, Petra
Kögl, Mariella
Fellner, Franz
Forstner, Thomas
Mangesius, Stephanie
Guger, Michael
Ransmayr, Gerhard http://orcid.org/0000-0001-9982-1420
Funding for this research was provided by:
Oesterreichische Nationalbank (Project number 13240)
Kepler Universitätsklinikum Linz
Article History
Received: 11 May 2021
Accepted: 1 July 2021
First Online: 22 July 2021
Declarations
:
: Lukas Kellermair received honoraria as a speaker from AbbVie GmbH. Alexandra Fuchs has nothing to declare. Christian Eggers has nothing to declare. Petra Schwingenschuh received consulting honoraria from AbbVie GmbH. Mariella W. Kögl received honoraria as a speaker and consulting honoraria from AbbVie GmbH. Franz Fellner has nothing to declare. Thomas Forstner has nothing to declare. Stephanie Mangesius has nothing to declare. Michael Guger received support and honoraria for research, consultation, lectures and education from Almirall, Bayer, Biogen, Celgene, Genzyme, MedDay, Merck, Novartis, Octapharma, Roche, Sanofi Aventis, Shire and TEVA ratiopharm. Gerhard Ransmayr received honoraria as a speaker and research support from AbbVie GmbH, Alpine Market Research, FFG, Grünenthal, MedAhead, Novartis Pharma GmbH, Ratiopharm, Roche Austria GmbH, Sanofi Aventis GmbH, UCB Pharma GmbH.
: The study was conducted according to the Declaration of Helsinki and approved by the local ethics review board (Ethikkommission des Landes Oberösterreich; FTLA Study, Protocol Number 254).
: Written informed consent was obtained from the patients and their caring family members.
: Not applicable.